泰利福 2025年度报告

Driving Transformation2025 Annual Report Financial Highlights From Continuing Operations1(Dollars In Millions, Except Per Share Data) AdjustedEarningsPer Share2 Net CashProvided byOperatingActivities Driving Transformation Teleflex is committed to transforming our companyinto a global leader that can deliver maximum valueto shareholders. We work toward this goal by executing a proven strategy that focuses on drivingrevenues, expanding margins and earnings, optimizing our product portfolio,and advancing our corporate social responsibility efforts. Our steadycommitment to these initiatives enables us to generate long-term durablegrowth while fulfilling our core purpose:To improve the health and qualityof people’s lives. OurVision OurPortfolio OurCommitment encompasses an arrayof differentiated medicaldevices and innovativetechnologies that arebacked by hands-on clinicaleducation programs andsupported by a best-in-classglobal supply chain. is to provide medicalprofessionals with completehealthcare solutions thatcan help to improve patientoutcomes, reduce costs,and create efficiencies. is to be the most trustedpartner in the worldof healthcare to all of ourconstituents, includingvendors, suppliers,customers, and regulators. Empowering thefuture of healthcare Dear Shareholders 2025 Highlights:• We acquired substantially all of Biotronik’sVascular Intervention business,strengthening ourposition in the high-growth coronary and peripheralvascular markets. •We took steps to separate our Acute Care,Interventional Urology, and OEM business unitsfrom the rest of our company. •We entered definitive agreements to divest theseassetsfor a combined total of $2.03 billion. •We accelerated our share repurchase activities,executing the remaining authorized amount of$300 million and authorizing a new $1 billion sharerepurchase program. We accomplished these goals while maintaining a sharpfocus on building excellence across our business—especially in the areas of quality control and our globalsupply chain. Collectively, our 2025 achievementsdemonstrate Teleflex’s agility and reflect the exceptionalcaliber of our employees. I thank each of them fortheir contributions to our strategic objectives and theirongoing commitment to our mission. Dr. Stephen K. Klasko, M.D.Chairman of the Board Driving TransformationTeleflex maintains a disciplined focus on creating In 2025, we executed a seriesof strategic initiatives designedtotransform Teleflexinto aleading medical device companywith a focus ongeneratinglong-term value. We tooksteps to significantlystreamlineour business, narrowing ourfocus to the critical care andhigh-acuity hospital end-markets,and we made a key acquisitionthatstrengthened anddiversifiedour Interventionalbusiness. We enter 2026 with a solidfoundation to drive our continuedtransformation and accelerateourglobal growth. long-term shareholder value. This effort encompassesstrategic portfolio actions that enable us to returncapital to shareholders while making targetedbusiness investments. In 2025, we initiated acomprehensive transformation designed to prepareTeleflex for accelerated growth. We began streamliningour operations and sharpening our focus on high-acuity and emergent care markets. This includedtaking steps to separate our Acute Care, InterventionalUrology, and OEM business units from the rest ofour company and entering into definitive agreementsto sell these assets. This initiative will significantly streamline our operations,leaving us with three highly complementary businessunits—Vascular, Interventional, and Surgical. Theresult will be a more focused Teleflex, supportedby a simplified operating model, a leaner manufacturingfootprint, and a sharper management focus. Webelieve this will help us unlock opportunities forgrowth and margin improvement and compete moreeffectively in high-innovation hospital and emergentcare markets. We expect to complete the divestitures in the secondhalf of 2026, generating gross cash proceedsof $2.03 billion. This is expected to enhance ourfinancial flexibility and support disciplined capitaldeployment, including increasing our investmentin R&D to fund innovation, reducing debt leverageto strengthen our balance sheet, returning capitalto shareholders through initiatives such as sharerepurchases, and making opportunistic tuck-inacquisitions that support our long-term growth. Fueling InnovationOur deep commitment to innovation has made Teleflex a market leader. We are continuingto leverage this capability to strengthen ourcompetitive position across our core businesses.This includes building our global leadership positionin Vascular by launching next-generation atomizationdevices, hemostatic products, and other traumaproducts. In Interventional, we are investing inadvanced coronary and peripheral vascular devices.And in Surgical, we are developing new productsthat address gaps in the manual ligation, autoligation, and ENT instrumentation markets. We